Table 2.
Incidence (per 100 person-years) of outcomes among the ACEi and ARB users after propensity score weighting
| Incidence (95 % CI) | Hazard ratio (95 % CI) | |||
|---|---|---|---|---|
| ACEi (n = 6898) | ARB (n = 12,758) | ACEi vs. ARB | P value | |
| MACE | ||||
| Any MACEa | 9.33 (8.90−9.76) | 9.62 (9.16−10.08) | 1.03 (0.96−1.10) | 0.4244 |
| Cogestive heart failure | 1.48 (1.33−1.63) | 1.51 (1.35−1.67) | 1.06 (0.91−1.22) | 0.4538 |
| Stroke | 3.78 (3.53−4.03) | 3.56 (3.31−3.82) | 1.12 (1.02−1.24) | 0.0230 |
| Malignant dysrhythmia | 0.16 (0.12−0.21) | 0.15 (0.10−0.20) | 1.14 (0.73−1.77) | 0.5571 |
| Cardiogenic shock | 0.03 (0.01−0.06) | 0.04 (0.02−0.07) | 0.81 (0.31−2.07) | 0.6547 |
| MI or PCI | 1.77 (1.61−1.93) | 2.19 (2.00−2.39) | 0.89 (0.78−1.01) | 0.0646 |
| CABG | 0.18 (0.13−0.23) | 0.22 (0.16−0.28) | 0.89 (0.60−1.31) | 0.5438 |
| Thrombolysis therapy | 0.00 (0.00−0.02) | 0.02 (0.01−0.05) | 0.19 (0.02−1.66) | 0.1339 |
| ESRD | 0.44 (0.36−0.52) | 0.63 (0.53−0.73) | 0.69 (0.54−0.88) | 0.0025 |
ACEi angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, CI confidence interval, MACE major adverse cardiovascular disease, MI myocardial infarction, CHF cogestive heart failure, PCI percutaneous coronary intevention, CABG coronary artery bypass graft surgery, ESRD end stage renal disease
aMACE = CHF or stroke or malignant dysrhythmia or cardiogenic shock or MI or PCI or CABG or thrombolysis therapy